MicroRNA-Dependent Mechanisms Underlying the Function of a β-Amino Carbonyl Compound in Glioblastoma Cells

Area of Science:

• Neuro-oncology
• Molecular Biology
• Drug Discovery

Background:

• Glioblastoma (GB) is an aggressive brain tumor with poor prognosis.
• Current treatments for glioblastoma are limited in efficacy.
• Beta-amino carbonyl (β-AC) compounds are being investigated for anticancer properties.

Purpose of the Study:

• To evaluate the efficacy of a novel β-AC compound, SHG-8, against glioblastoma cells.
• To investigate the molecular mechanisms underlying SHG-8's effects, including its impact on the miRNome.
• To assess the potential bioavailability of SHG-8 in the human body, particularly its ability to cross the blood-brain barrier.

Main Methods:

• In vitro assays using U87MG and U251MG glioblastoma cell lines.
• Small RNA sequencing (sRNA-seq) to analyze microRNA expression changes.
• Annexin V and acridine orange/ethidium bromide staining to detect apoptosis.
• Real-time polymerase chain reaction (RT-qPCR) to validate gene expression.
• In silico analysis for blood-brain barrier penetration prediction.

Main Results:

• SHG-8 demonstrated significant cytotoxicity, inhibiting proliferation and migration of glioblastoma cells.
• Treatment with SHG-8 induced reactive oxygen species (ROS) production and apoptosis in cancer cells.
• sRNA-seq revealed altered microRNA profiles, including upregulation of miR-3648 and downregulation of miR-7973.
• RT-qPCR confirmed downregulation of the oncogene CORO1C, involved in the Wnt/β-catenin pathway.
• In silico analysis suggested SHG-8 can potentially cross the blood-brain barrier.

Conclusions:

• SHG-8 exhibits potent anti-glioblastoma effects in vitro.
• The compound's mechanism may involve microRNA deregulation and inhibition of CORO1C.
• SHG-8 shows potential as a therapeutic agent for glioblastoma, warranting further investigation for its bioavailability.